aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
NuShores Biosciences was founded to commercialize patented bone and tissue regeneration technologies. The company's core mission is to innovate and provide effective solutions for bone regeneration across various medical needs, including craniomaxillofacial, dental, limb, and spinal applications. Their flagship product, the NuCress™ scaffold, is designed to heal large segmental bone defects with customizable design, shape, and form, offering shelf-life stability and tolerance over a wide range of storage conditions. NuShores aims to address the lack of satisfactory solutions in the current market for major bone injuries.
Notable individuals affiliated with NuShores Biosciences include key researchers and industry experts who have contributed to the development of their proprietary technologies. The company has garnered attention from investors interested in advancing medical technologies. Key achievements include the development and refinement of the NuCress™ scaffold, although it has yet to receive FDA approval. Overall, NuShores Biosciences is making a significant impact by pushing the boundaries of bone regeneration technology, aiming to improve patient outcomes and fill a critical gap in medical treatments.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Bone Regeneration
Technology
Biotech
Tags
Healthtech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was NuShores Biosciences founded?
NuShores Biosciences was founded in 2014.
Where is NuShores Biosciences’s headquarters located?
NuShores Biosciences’s headquarters is located in Little Rock, AR, US.
When was NuShores Biosciences’s last funding round?
NuShores Biosciences’s most recent funding round was for $100k (USD) in January 2020.
How many employees does NuShores Biosciences have?
NuShores Biosciences has 15 employees as of Feb 5, 2024.
How much has NuShores Biosciences raised to-date?
As of July 05, 2023, NuShores Biosciences has raised a total of $1.9M (USD) since Jan 14, 2020.
Add Comparison
Total Raised to Date
$1.9M
USD
Last Update Jan 14, 2020
Last Deal Details
$100k
USD
Jan 14, 2020
Grant
Total Employees Over Time
15
As of Feb 2024
NuShores Biosciences Address
Little Rock,
Arkansas
72204
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts